IP Library Granted Patent US 11,766,405
Granted Patent B2
US 11,766,405 · App. 16/876,505 · Granted Sep 26, 2023

Process for the preparation of a freeze-dried pharmaceutical composition containing mitomycin C

Inventors: Sonja Schuldt-Lieb (Hamburg, DE); Sebastian Bialleck (Hamburg, DE); Ingo Guhde (Hamburg, DE); Michaela Rehberg (Hamburg, DE)
Assignee: MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH
A61K9/19A61K9/0019A61K9/08A61K9/1617A61K9/1623A61K9/1641A61K31/407A61K47/10A61K47/18A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,766,405
App. No.
16/876,505
Granted
Sep 26, 2023
Kind
B2
Abstract

A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Claims (8)

1. Freeze-dried pharmaceutical composition comprising mitomycin C and urea, wherein the composition comprises urea at a concentration of 0.2 to 0.99 grams (g) per gram of composition.

2. Composition according to claim 1 , which comprises urea at a concentration of 0.5 to 0.99 g per gram of composition.

3. Composition according to claim 2 , which comprises urea at a concentration of 0.8 to 0.95 g per gram of composition.

4. Composition according to claim 3 , which comprises urea at a concentration of 0.93 to 0.94 g per gram of composition.

5. The composition according to claim 1 , which comprises the impurities D1, D2 and albomitomycin C in a total quantity of less than 2.0%, wherein the quantity of these impurities is determined according to the impurities process according to Ph Eur 8.0 Mitomycin Monograph January 2008: 1655.

6. The composition according to claim 5 , which comprises the impurities D1, D2 and albomitomycin C in a total quantity of less than 1.0%, wherein the quantity of these impurities is determined according to the impurities process according to Ph Eur 8.0 Mitomycin Monograph January 2008: 1655.

7. The composition according to claim 6 , which comprises the impurities D1, D2 and albomitomycin C in a total quantity of less than 0.6%, wherein the quantity of these impurities is determined according to the impurities process according to Ph Eur 8.0 Mitomycin Monograph January 2008:1655.

8. Freeze-dried pharmaceutical composition comprising mitomycin C, wherein the composition is obtainable by a process comprising freeze-drying a solution of mitomycin C, wherein the solution comprises a mixture of tert.-butanol and water, and wherein the mixture comprises 84 to 95 wt. % tert.-butanol.

Assignments (3)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: SCHULDT-LIEB, SONJA; BIALLECK, SEBASTIAN; GUHDE, INGO; REHBERG, MICHAELA
To: MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH
Reel/Frame 052688/0070 →
Priority Claims (1)
EP 13189775 · Oct 22, 2013 · regional
Continuity (2)
Division 15031519
Related Publication 20200276128A1 · Sep 3, 2020